Bionano's Optical Genome Mapping Validated in Three Studies for High-Risk Blood Cancers — Bionano Genomics, Inc.

Event summary

Three peer-reviewed studies published in September 2026 demonstrate Bionano's Optical Genome Mapping (OGM) can detect high-risk genomic alterations in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and therapy-related myeloid neoplasms (t-MN) that standard methods miss.
MD Anderson study found OGM-identified chromoanagenesis in 15.9% of MDS cases, with median survival of 9.9 months for CAG-positive patients.
University of Oulu study detected clinically relevant structural variants in 46% of cytogenetically normal AML cases using OGM.
Spanish multicenter study showed OGM refined risk classification in 52% of karyotypically abnormal cases and detected actionable alterations in 9.8% of normal-karyotype cases.

The big picture

These studies position OGM as a potential game-changer in hematologic cancer diagnostics, offering more comprehensive genomic insights than traditional methods. The findings suggest OGM could enable earlier identification of high-risk patients who might benefit from aggressive therapies or targeted clinical trials. This validation comes at a time when precision oncology is increasingly focused on structural genomic alterations beyond single-gene mutations.

What we're watching

Clinical Adoption: How quickly OGM will be integrated into standard diagnostic workflows for high-risk hematologic malignancies.
Prognostic Refinement: Whether OGM findings will lead to meaningful revisions of existing risk-stratification systems like IPSS-R and ELN2022.
Therapeutic Impact: The pace at which OGM-identified genomic markers translate into targeted treatment options for ultra-high-risk patient subsets.